Q2 2026 Evolent Health, Inc. Earnings Call Transcript
Key Points
- Evolent Health Inc (EVH) reported strong Q2 2026 results with total revenue of $653 million, up 31% quarter-over-quarter, and adjusted EBITDA of $28 million, up 27% quarter-over-quarter, exceeding expectations.
- The company raised its full-year 2026 revenue guidance to $2.6-$2.7 billion and narrowed adjusted EBITDA guidance to $120-$135 million, reflecting increased confidence in its outlook.
- Evolent Health Inc (EVH) announced a new oncology Performance Suite partnership covering approximately 1.5 million lives across 11 states, expected to generate about $300 million in annualized revenue, and a contract extension with a regional Blue Cross plan, demonstrating strong cross-sell opportunities.
- The company successfully renewed three of its largest customers in 2026, providing significant visibility into 2027 revenue growth of more than 25%.
- Evolent Health Inc (EVH)'s Auth Intelligence platform is scaling effectively, with auto-approval rates improving by up to 20 percentage points and over one-third of previously manual authorization volume now evaluated through AI, supporting long-term margin targets.
- Early indicators from the Highmark and Aetna Performance Suite launches are positive, with clinical and provider engagement rates trending above targets, and claims performance in line with expectations.
- Evolent Health Inc (EVH)'s Q2 2026 medical expense ratio (MER) was 95%, up 200 basis points from Q1, reflecting the expected impact of the Highmark launch and higher acuity in exchange populations.
- The company faces significant headwinds in 2027, including an expected 20% decline in Medicaid expansion members, which translates to a 4-5% membership decline in Medicaid, and further exchange membership attrition.
- Evolent Health Inc (EVH) expects Specialty Tech and Services revenue to be flat to down in 2027 due to membership headwinds, and the company is absorbing ongoing client-specific market exits and attrition.
- The company's operating cash flow in Q2 was unusually low due to the repayment of pass-through PBM proceeds, and full-year 2026 cash flow from operations is expected to be only $10-$20 million after interest expenses.
- Evolent Health Inc (EVH) has a significant net debt of $808.3 million and is actively working to address its 2029 maturities, with a clear path to improving leverage ratios but no definitive plan yet.
- The company anticipates a more modest Q2 to Q3 adjusted EBITDA increase of $4-$7 million due to the timing of favorable prior year development, and expects MER to remain elevated in Q3 before improving in Q4.
Welcome to the Evolent earnings conference call for the second quarter ended June 30, 2026. As a reminder, this conference call is being recorded. Your hosts for the call today from Evolent are Seth Blackley, Chief Executive Officer; and Mario Ramos, Chief Financial Officer. This call will be archived and available later this evening and for the next week via the webcast on the company's website in the section titled Investor Relations.
This conference call will contain forward-looking statements under US federal laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. A description of some of the risks and uncertainties can be found in the company's reports that are filed with the Securities and Exchange Commission, including cautionary statements included in our current and periodic filings.
For additional information on the company's results and outlook, please refer to our second quarter press release issued earlier today.
Finally, as a reminder, reconciliations of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
